Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Sparano

Showing results (181-190 of 293) with videos related to

Pageof 30
Sort By:
JAMA Oncology|June 17, 2021
Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical TrialBetina Yanez, Robert J Gray, Joseph A Sparano, et al.
Journal of the National Cancer Institute|May 19, 2021
Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast CancerOlga Kantor, Tari A King, Steven Shak, et al.
Clinical Breast Cancer|June 5, 2012
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trialsVicente Valero, Eduard Vrdoljak, Binghe Xu, et al.
Oncotarget|October 13, 2016
Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African AmericansBryan P Schneider, Dongbing Lai, Fei Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphomaJohn P Leonard, Brian K Link, Christos Emmanouilides, et al.
Cancer Investigation|September 26, 2014
Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancerKevin Kalinsky, Emerson A Lim, Eleni Andreopoulou, et al.
Annals of Surgical Oncology|July 28, 2022
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORxOlga Kantor, Harold J Burstein, Tari A King, et al.
Cancer|October 6, 2021
Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudySofia F Garcia, Robert J Gray, Joseph A Sparano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2015
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 ProteinMurali Janakiram, Jordan M Chinai, Susan Fineberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology GroupAmye J Tevaarwerk, Molin Wang, Fengmin Zhao, et al.
Pageof 30

Showing results (181-190 of 293) with videos related to

Sort By:
Pageof 30
JAMA Oncology|June 17, 2021
Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical TrialBetina Yanez, Robert J Gray, Joseph A Sparano, et al.
Journal of the National Cancer Institute|May 19, 2021
Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast CancerOlga Kantor, Tari A King, Steven Shak, et al.
Clinical Breast Cancer|June 5, 2012
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trialsVicente Valero, Eduard Vrdoljak, Binghe Xu, et al.
Oncotarget|October 13, 2016
Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African AmericansBryan P Schneider, Dongbing Lai, Fei Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphomaJohn P Leonard, Brian K Link, Christos Emmanouilides, et al.
Cancer Investigation|September 26, 2014
Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancerKevin Kalinsky, Emerson A Lim, Eleni Andreopoulou, et al.
Annals of Surgical Oncology|July 28, 2022
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORxOlga Kantor, Harold J Burstein, Tari A King, et al.
Cancer|October 6, 2021
Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudySofia F Garcia, Robert J Gray, Joseph A Sparano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2015
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 ProteinMurali Janakiram, Jordan M Chinai, Susan Fineberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology GroupAmye J Tevaarwerk, Molin Wang, Fengmin Zhao, et al.
Pageof 30